SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:1SXP • DE000A3ENQ51

14.15 EUR
-0.29 (-2.01%)
Last: Feb 4, 2026, 12:50 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to 1SXP. 1SXP was compared to 18 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year 1SXP was profitable.
  • In the past year 1SXP had a positive cash flow from operations.
  • In the past 5 years 1SXP has always been profitable.
  • 1SXP had a positive operating cash flow in each of the past 5 years.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • The Return On Assets of 1SXP (9.16%) is better than 88.89% of its industry peers.
  • 1SXP has a better Return On Equity (16.42%) than 88.89% of its industry peers.
  • 1SXP's Return On Invested Capital of 13.06% is amongst the best of the industry. 1SXP outperforms 88.89% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is above the industry average of 9.98%.
Industry RankSector Rank
ROA 9.16%
ROE 16.42%
ROIC 13.06%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • With a decent Profit Margin value of 14.85%, 1SXP is doing good in the industry, outperforming 77.78% of the companies in the same industry.
  • In the last couple of years the Profit Margin of 1SXP has grown nicely.
  • 1SXP has a Operating Margin of 18.95%. This is in the better half of the industry: 1SXP outperforms 77.78% of its industry peers.
  • 1SXP's Operating Margin has improved in the last couple of years.
  • With a Gross Margin value of 33.71%, 1SXP is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
  • 1SXP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.95%
PM (TTM) 14.85%
GM 33.71%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

6

2. Health

2.1 Basic Checks

  • 1SXP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • 1SXP has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 1SXP has about the same amount of shares outstanding.
  • Compared to 1 year ago, 1SXP has an improved debt to assets ratio.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • 1SXP has a debt to FCF ratio of 2.43. This is a good value and a sign of high solvency as 1SXP would need 2.43 years to pay back of all of its debts.
  • 1SXP's Debt to FCF ratio of 2.43 is amongst the best of the industry. 1SXP outperforms 94.44% of its industry peers.
  • 1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • 1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 2.43
Altman-Z N/A
ROIC/WACC1.37
WACC9.57%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • 1SXP has a Current Ratio of 1.50. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • 1SXP's Current ratio of 1.50 is fine compared to the rest of the industry. 1SXP outperforms 72.22% of its industry peers.
  • 1SXP has a Quick Ratio of 1.12. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • 1SXP's Quick ratio of 1.12 is fine compared to the rest of the industry. 1SXP outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.5
Quick Ratio 1.12
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

  • 1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.02%.
  • Measured over the past years, 1SXP shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.78% on average per year.
  • Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 3.04% in the last year.
  • 1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.04% yearly.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%

3.2 Future

  • 1SXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.98% yearly.
  • Based on estimates for the next years, 1SXP will show a small growth in Revenue. The Revenue will grow by 7.13% on average per year.
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y12.98%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 14.59 indicates a correct valuation of 1SXP.
  • Based on the Price/Earnings ratio, 1SXP is valued cheaper than 88.89% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of 1SXP to the average of the S&P500 Index (28.18), we can say 1SXP is valued slightly cheaper.
  • 1SXP is valuated correctly with a Price/Forward Earnings ratio of 14.17.
  • Based on the Price/Forward Earnings ratio, 1SXP is valued cheaper than 94.44% of the companies in the same industry.
  • 1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.51.
Industry RankSector Rank
PE 14.59
Fwd PE 14.17
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 1SXP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. 1SXP is cheaper than 88.89% of the companies in the same industry.
  • 66.67% of the companies in the same industry are cheaper than 1SXP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 60.61
EV/EBITDA 8.32
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)4.9
PEG (5Y)1.06
EPS Next 2Y8.11%
EPS Next 3Y9.33%

More info and screens

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.25%, 1SXP has a reasonable but not impressive dividend return.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.43. 1SXP pays more dividend than 94.44% of the companies in the same industry.
  • Compared to the average S&P500 Dividend Yield of 1.83, 1SXP is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.25%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 16.45% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.45%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (2/4/2026, 12:50:36 PM)

14.15

-0.29 (-2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-11
Earnings (Next)02-11
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.13B
Revenue(TTM)986.21M
Net Income(TTM)146.45M
Analysts75.79
Price Target21.23 (50.04%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.25%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP16.45%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.27%
Min EPS beat(2)-3.5%
Max EPS beat(2)-1.05%
EPS beat(4)1
Avg EPS beat(4)-3.37%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)3
Avg EPS beat(8)1.1%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.13%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)-1.99%
Revenue beat(4)1
Avg Revenue beat(4)-1.96%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.15%
PT rev (3m)-29.16%
EPS NQ rev (1m)-19.86%
EPS NQ rev (3m)-31.31%
EPS NY rev (1m)-2.62%
EPS NY rev (3m)-17.49%
Revenue NQ rev (1m)-3.33%
Revenue NQ rev (3m)-8.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.42%
Valuation
Industry RankSector Rank
PE 14.59
Fwd PE 14.17
P/S 2.16
P/FCF 60.61
P/OCF 11.84
P/B 2.39
P/tB 2.47
EV/EBITDA 8.32
EPS(TTM)0.97
EY6.86%
EPS(NY)1
Fwd EY7.06%
FCF(TTM)0.23
FCFY1.65%
OCF(TTM)1.19
OCFY8.44%
SpS6.55
BVpS5.92
TBVpS5.72
PEG (NY)4.9
PEG (5Y)1.06
Graham Number11.37
Profitability
Industry RankSector Rank
ROA 9.16%
ROE 16.42%
ROCE 16.33%
ROIC 13.06%
ROICexc 13.46%
ROICexgc 13.83%
OM 18.95%
PM (TTM) 14.85%
GM 33.71%
FCFM 3.57%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 2.43
Debt/EBITDA 0.3
Cap/Depr 182.22%
Cap/Sales 14.68%
Interest Coverage 11.84
Cash Conversion 67.54%
Profit Quality 24.01%
Current Ratio 1.5
Quick Ratio 1.12
Altman-Z N/A
F-Score6
WACC9.57%
ROIC/WACC1.37
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%0%
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y12.98%
Revenue 1Y (TTM)3.04%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.44%
Revenue Next Year4.39%
Revenue Next 2Y6.84%
Revenue Next 3Y6.72%
Revenue Next 5Y7.13%
EBIT growth 1Y5.25%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year43.48%
EBIT Next 3Y20.64%
EBIT Next 5Y16.53%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.


Can you provide the financial health for 1SXP stock?

The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 6 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 2.98% in the next year.